Q1 Earnings Estimate for HOWL Issued By Leerink Partnrs

Key Points

• Leerink Partners estimates Werewolf Therapeutics will report Q1 2026 earnings of **($0.39)** per share, with an overall consensus estimate for the full year at **($1.56)** EPS.
• Bank of America decreased its price objective for Werewolf Therapeutics from **$9.00** to **$8.00**, maintaining a "buy" rating, while other analysts have varied target prices between **$3.00** and **$8.00**.
• Institutional investors hold **64.84%** of Werewolf Therapeutics' shares, with significant new positions taken by Jane Street Group and Deutsche Bank AG.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($0.39) per share for the quarter. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics' Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.51) EPS.

HOWL has been the topic of several other reports. Citigroup reiterated a "buy" rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Finally, Bank of America reduced their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, August 25th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Werewolf Therapeutics has an average rating of "Buy" and an average price target of $8.00.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL remained flat at $1.35 during trading on Friday. The stock had a trading volume of 115,433 shares, compared to its average volume of 127,681. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $4.18. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The firm has a 50-day moving average of $1.26 and a 200-day moving average of $1.13. The stock has a market cap of $61.74 million, a PE ratio of -0.82 and a beta of 0.64.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp lifted its stake in shares of Werewolf Therapeutics by 7.3% in the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company's stock valued at $362,000 after purchasing an additional 16,640 shares during the period. D. E. Shaw & Co. Inc. bought a new position in Werewolf Therapeutics during the 4th quarter valued at approximately $26,000. MPM Bioimpact LLC increased its position in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after buying an additional 20,799 shares in the last quarter. Bridgeway Capital Management LLC increased its position in Werewolf Therapeutics by 24.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company's stock valued at $162,000 after buying an additional 21,500 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock valued at $93,000 after buying an additional 23,852 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.